Radius Health Inc. (NASDAQ:RDUS) shares shot up 4.1% during mid-day trading on Friday . The stock traded as high as $41.07 and last traded at $40.58, with a volume of 228,030 shares. The stock had previously closed at $39.00.

Several analysts have recently weighed in on the stock. Zacks Investment Research raised shares of Radius Health from a “sell” rating to a “hold” rating in a report on Monday, May 2nd. Canaccord Genuity reaffirmed a “buy” rating on shares of Radius Health in a report on Tuesday, May 31st. Cowen and Company assumed coverage on shares of Radius Health in a report on Friday, May 6th. They set an “outperform” rating for the company. HC Wainwright assumed coverage on shares of Radius Health in a report on Monday, May 23rd. They set a “buy” rating and a $55.00 price objective for the company. Finally, Goldman Sachs Group Inc. assumed coverage on shares of Radius Health in a report on Wednesday, March 30th. They set a “neutral” rating and a $37.00 price objective for the company. Three equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $70.07.

The stock’s market cap is $1.74 billion. The firm has a 50-day moving average price of $37.61 and a 200 day moving average price of $35.92.

Radius Health (NASDAQ:RDUS) last issued its quarterly earnings results on Thursday, May 5th. The biopharmaceutical company reported ($0.94) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.74) by $0.20. During the same period in the prior year, the company earned ($0.47) EPS. The business’s revenue for the quarter was up .0% on a year-over-year basis. Equities analysts anticipate that Radius Health Inc. will post ($3.71) EPS for the current year.

Several hedge funds have recently modified their holdings of RDUS. Jennison Associates purchased a new stake in shares of Radius Health during the third quarter worth $40,041,000. Wells Fargo & Company MN increased its stake in shares of Radius Health by 7.5% in the fourth quarter. Wells Fargo & Company MN now owns 422,217 shares of the biopharmaceutical company’s stock worth $25,984,000 after buying an additional 29,601 shares during the period. Dimensional Fund Advisors LP purchased a new stake in shares of Radius Health during the fourth quarter worth $1,362,000. New York State Common Retirement Fund increased its stake in shares of Radius Health by 36.0% in the fourth quarter. New York State Common Retirement Fund now owns 69,048 shares of the biopharmaceutical company’s stock worth $4,249,000 after buying an additional 18,259 shares during the period. Finally, American Century Companies Inc. increased its stake in shares of Radius Health by 25.2% in the fourth quarter. American Century Companies Inc. now owns 41,377 shares of the biopharmaceutical company’s stock worth $2,546,000 after buying an additional 8,334 shares during the period.

Radius Health, Inc is a science-driven biopharmaceutical company focused on developing therapeutics for patients with osteoporosis, oncology and endocrine diseases. The Company’s lead product candidate is the investigational drug abaloparatide for subcutaneous injection (abaloparatide-SC), which has completed Phase III development for potential use in the reduction of fracture risk in postmenopausal women with osteoporosis.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.